We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Impax Labs' Parkinson's drug aces late-stage clinical trial

Impax Labs' Parkinson's drug aces late-stage clinical trial

March 18, 2011
CenterWatch Staff

Hayward, Calif.-based Impax Laboratories said the Parkinson's drug it in-licensed from GlaxoSmithKline last year—its second attempt at an extended-release version of caribidopa-levadopa—beat out the standard of care for controlling a key symptom of the disease in a late-stage study, according to FiercePharma.

The primary endpoint of the IPX066 trial was the percentage of "off time"—when patients' medication effect has worn off and there is a return of Parkinson's symptoms—during waking hours. IPX066 demonstrated a 37% improvement from baseline compared to a 17% improvement from baseline for the standard treatment.

"With the successful completion of this ADVANCE-PD trial and the APEX-PD trial in patients with early PD, we have completed the two required phase III trials for a New Drug Application as agreed with the FDA. We are working diligently to file an NDA in the fourth quarter of 2011," said Impax CSO Dr. Suneel Gupta.

Just three months ago GlaxoSmithKline signed a $186 million licensing deal for the program, gaining ex-U.S. rights with an $11.5 million upfront payment and a promise of $175 million in milestones.

The FDA rejected a similar product from Impax, Vadova, in early 2008. A few months later the company announced plans to launch a new development program to create a next-generation carbidopa-levodopa therapy that could leverage the experience it had gained trying to get an approval for Vadova.

United States Clinical Intelligence

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing